Rilzabrutinib a BTK inhibitor

Multi-Immune Modulation With Rilzabrutinib

Rilzabrutinib is an oral, covalent, reversible, highly specific BTK inhibitor

BTK inhibition with rilzabrutinib modulates multiple immune pathways without causing broad immunosuppression

Rilzabrutinib's immunomodulatory effects: Rebalancing innate and adaptive immunity

In vitro and biomarker studies, rilzabrutinib’s immunomodulatory effects were confirmed:

BTK inhibition: Rilzabrutinib acts via multi-immune modulation targeting key aspects of complex immune dysregulation in multiple diseases¹⁰

BCR, B-cell receptor; BTK, Bruton’s tyrosine kinase; Cys, cysteine; FcεR, Fc epsilon receptor; FcγR, Fc gamma receptor; IC, immune complex; IgE, immunoglobulin E; IgG, immunoglobulin G; IgM, immunoglobulin M; IL, interleukin; ITP, immune thrombocytopenia; NET, neutrophil extracellular trap; NLRP, NOD-like receptor protein with a PYRIN domain; Rilza, rilzabrutinib; ROS, reactive oxygen species; SCD, sickle cell disease; TLR, toll-like receptor; TNF-α, tumor necrosis factor alpha; wAIHA, warm autoimmune hemolytic anemia.

Langrish CL, et al. J Immunol. 2021;206:1454-1468.
Owens TD, et al. J Med Chem. 2022;65(7):5300-5316
Kuter DJ, et al. Ther Adv Hematol. 2023;14:20406207231205431.
Rip J, et al. Crit Rev Immunol. 2018;38(1):17-62.
Jongstra-Bilen J, et al. J Immunol. 2008;181(1):288-298.
Zhang D, et al. Molecules. 2021;26(16):4907.
Garg N, et al. J Clin Med. 2022;11(20):6139.
Desai JV, et al. J Clin Invest. 2024;134(12):e176142.
Daak A, et al. Presented at American Society of Hematology Congress 2024. Poster 4282.
Kuter DJ, Ghanima W. Immunotherapy. 2025:1-16.
Cooper N, et al. Presented at EHA 2025. Poster number: PS2197.